Search

Amphastar Pharmaceuticals Inc

Abierto

SectorSanidad

19.79 -1.98

Resumen

Variación precio

24h

Actual

Mínimo

19.62

Máximo

20.32

Métricas clave

By Trading Economics

Ingresos

-18M

6.4M

Ventas

-12M

171M

P/B

Media del Sector

11.554

64.641

BPA

0.42

Margen de beneficios

3.751

Empleados

1,976

EBITDA

-5.4M

33M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+8.8% upside

Dividendos

By Acuity

Próximas Ganancias

6 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-167M

846M

Apertura anterior

21.77

Cierre anterior

19.79

Noticias sobre sentimiento de mercado

By Acuity

14%

86%

19 / 340 Clasificación en Healthcare

Amphastar Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 ago 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading higher, reaching a session high amid positive market conditions and falling oil prices influencing investor sentiment.

31 jul 2026, 19:36 UTC

Amphastar Pharmaceuticals is declining today, continuing a downward trend since Thursday. The stock reached a session low earlier this morning amid broader market volatility.

30 jul 2026, 19:28 UTC

Amphastar Pharmaceuticals Inc. shares are lower amid significant downward pressure in the Pharmaceuticals sub-sector, reflecting broader sector weakness during Thursday's session.

29 jul 2026, 20:41 UTC

Amphastar Pharmaceuticals shares are lower in after-market trading, continuing a decline amid rising crude oil prices and geopolitical tensions in the Middle East.

28 jul 2026, 20:02 UTC

Amphastar Pharmaceuticals shares are higher today, diverging from a broader market decline amid a sell-off in technology stocks across Asian markets.

24 jul 2026, 19:06 UTC

Amphastar Pharmaceuticals is trading higher, supported by a pullback in crude oil prices, which has eased some inflationary pressures affecting investor sentiment.

22 jul 2026, 20:06 UTC

Amphastar Pharmaceuticals Inc shares are lower today, continuing a four-session decline amid market uncertainty ahead of the Federal Reserve meeting on July 29.

21 jul 2026, 19:46 UTC

Amphastar Pharmaceuticals Inc is trading lower, continuing a three-session decline. No specific news was identified to explain the stock's performance.

20 jul 2026, 19:56 UTC

Amphastar Pharmaceuticals is gaining modestly during Monday's session amid mixed market conditions and geopolitical tensions affecting oil prices and inflation concerns.

Comparación entre iguales

Cambio de precio

Amphastar Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

8.8% repunte

Estimación a 12 Meses

Media 22 USD  8.8%

Máximo 30 USD

Mínimo 19 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Amphastar Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

6 ratings

0

Comprar

5

Mantener

1

Vender

Sentimiento

By Acuity

19 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
help-icon Live chat